Focus on the opportunities

AltaThera is dedicated to optimizing care, starting with atrial fibrillation

AltaThera Pharmaceuticals is a hospital-focused pharmaceutical company. Our first product is an IV formulation of the 2nd most widely used antiarrhythmic drug in the US. [Need reference]

ATRIAL FIBRILLATION IS GROWING IN PREVALENCE

US prevalence is expected to increase from 6 million to 12.1 million by 2030

Lifetime risk of atrial fibrillation is ~1 in 4 adults over 40 years of age [Benjamin 1998]

There are 750,000 hospitalizations for atrial fibrillation annually in the US

Current treatment approach for atrial fibrillation

Sotalol IV offers a different, faster administration

PRODUCT INFORMATION

News